A ROLE FOR THE GLUCOCORTICOID RECEPTOR IN CARDIAC REMODELLING?

doi:10.1136/heartjnl-2012-303148a.7

R V Richardson,* C J Kenyon, A J W Thomson, C M Moran, G A Gray, K E Chapman. *Centre for Cardiovascular Science, The University of Edinburgh, The Queen's Medical Research Institute, Edinburgh, EH16 4TJ, UK*

Variation in the glucocorticoid receptor (GR) associates with relative glucocorticoid resistance, hypertension and increased cardiovascular disease risk in humans. Mice heterozygous for the glucocorticoid receptor (GR+/-) are similarly glucocorticoid resistant with raised circulating glucocorticoid levels and elevated blood pressure; susceptibility to heart disease is uncharacterised. Here we describe the cardiac phenotype of adult male GR+/- mice and show evidence of impaired cardiac remodelling in response to pharmacological challenge.

Heart weight (% body weight) is unchanged in 12 week old GR +/- mice (WT:0.57±0.03%, GR+/-:0.61±0.03%), but cardiomyocyte cross-sectional area is reduced (WT:240±21 µm², GR+/-:193±9.0 µm², p<0.05), and cardiac nuclei density is increased (nuclei/field; WT:67±1, GR+/-:74±2, p<0.05), suggesting GR+/- mice have more but smaller cardiomyocytes than WT. Whilst histological analysis does not reveal differences in fibrosis, cardiac levels of mRNA encoding connective tissue growth factor are reduced in GR+/- mice (WT:100±12%, GR+/-:65±4%, p<0.05) implying subtle alterations in pro-fibrotic signalling. Echocardiography demonstrates comparable cardiac function in 10 week old GR+/- and WT mice.

Intriguingly, preliminary data show cardiac hypertrophy in response to angiotensin II infusion (100 ng/kg-1 min-1 by osmotic mini-pump) is attenuated in GR+/- mice (heart weight/tibia length Vehicle: WT 7.47±0.326 mg/mm, GR+/-7.29 mg/mm; AngII: WT 8.66±0.249 mg/mm, GR+/-8.07±0.217 mg/mm, p<0.05 (AngII treatment)).

These data show that GR deficiency alters the size and number of cardiomyocytes and that, whilst adult GR+/- mice match WT cardiac function under basal conditions, cardiac remodelling following pathological challenge is attenuated. Further characterisation of the GR+/- cardiac phenotype may provide critical insights into how GR variation in humans increases risk of heart disease.